Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DRUG Bright Minds Biosciences	$43.96 +4.3%	$31.70	$0.94 ▼ $79.02	$309.65M	-6.07	56,394 shs	29,142 shs
DSGN Design Therapeutics	$5.26 +2.1%	$4.16	$2.60 ▼ $7.77	$299.55M	1.58	135,397 shs	176,513 shs
PYXS Pyxis Oncology	$1.34 +1.5%	$1.16	$0.83 ▼ $5.39	$83.10M	1.13	406,891 shs	1.33 million shs
RNAC Cartesian Therapeutics	$11.23 +2.5%	$11.67	$8.46 ▼ $26.50	$292M	0.44	52,936 shs	84,147 shs

7 Stocks to Buy And Hold Forever

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DRUG Bright Minds Biosciences	+4.34%	+5.12%	+47.12%	+51.53%	+4,167.96%
DSGN Design Therapeutics	+2.14%	-1.31%	+23.19%	+38.06%	+0.19%
PYXS Pyxis Oncology	+1.52%	+8.94%	+13.56%	+8.94%	-63.09%
RNAC Cartesian Therapeutics	+2.46%	-0.88%	-16.13%	+22.60%	-24.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DRUG Bright Minds Biosciences	2.6654 of 5 stars	3.6	2.0	3.3	2.5	0.0
DSGN Design Therapeutics	0.1619 of 5 stars	0.0	1.0	0.9	2.5	0.0
PYXS Pyxis Oncology	2.3154 of 5 stars	3.3	2.0	3.3	0.8	0.6
RNAC Cartesian Therapeutics	2.6051 of 5 stars	3.4	2.0	2.7	3.3	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DRUG Bright Minds Biosciences	3.13	Buy	$83.25	89.38% Upside
DSGN Design Therapeutics	0.00	N/A	N/A	N/A
PYXS Pyxis Oncology	2.60	Moderate Buy	$8.67	546.77% Upside
RNAC Cartesian Therapeutics	2.80	Moderate Buy	$40.00	256.19% Upside

Current Analyst Ratings Breakdown

Latest PYXS, DSGN, RNAC, and DRUG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2025	DRUG Bright Minds Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$85.00
8/19/2025	PYXS Pyxis Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
8/18/2025	PYXS Pyxis Oncology	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/9/2025	RNAC Cartesian Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$38.00
7/2/2025	DRUG Bright Minds Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$5.32 per share	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.74 per share	N/A
PYXS Pyxis Oncology	$16.15M	5.15	N/A	N/A	$1.41 per share	0.95
RNAC Cartesian Therapeutics	$38.91M	7.50	N/A	N/A	($0.10) per share	-112.30

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DRUG Bright Minds Biosciences	-$2.06M	-$0.93	N/A	N/A	N/A	N/A	-20.96%	-20.66%	N/A
DSGN Design Therapeutics	-$49.59M	-$1.12	N/A	N/A	N/A	N/A	-27.15%	-26.07%	11/6/2025 (Estimated)
PYXS Pyxis Oncology	-$77.33M	-$1.60	N/A	N/A	N/A	N/A	-68.56%	-52.14%	11/11/2025 (Estimated)
RNAC Cartesian Therapeutics	-$77.42M	-$52.83	N/A	N/A	N/A	N/A	N/A	-6.36%	11/6/2025 (Estimated)

Latest PYXS, DSGN, RNAC, and DRUG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q3 2025	DRUG Bright Minds Biosciences	-$0.59	-$0.53	+$0.06	-$0.53	N/A	N/A
8/14/2025	Q2 2025	PYXS Pyxis Oncology	-$0.36	-$0.30	+$0.06	-$0.30	N/A	$2.82 million
8/7/2025	Q1 2025	DSGN Design Therapeutics	-$0.32	-$0.34	-$0.02	-$0.34	N/A	N/A
8/7/2025	Q2 2025	RNAC Cartesian Therapeutics	-$0.76	$0.50	+$1.26	$0.50	$0.77 million	$0.30 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
PYXS Pyxis Oncology	N/A	N/A	N/A	N/A	N/A
RNAC Cartesian Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DRUG Bright Minds Biosciences	N/A	86.64	88.33
DSGN Design Therapeutics	N/A	25.13	25.13
PYXS Pyxis Oncology	N/A	5.65	7.75
RNAC Cartesian Therapeutics	N/A	13.33	13.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DRUG Bright Minds Biosciences	40.52%
DSGN Design Therapeutics	56.64%
PYXS Pyxis Oncology	39.09%
RNAC Cartesian Therapeutics	86.95%

Insider Ownership

Company	Insider Ownership
DRUG Bright Minds Biosciences	42.66%
DSGN Design Therapeutics	23.50%
PYXS Pyxis Oncology	10.60%
RNAC Cartesian Therapeutics	60.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DRUG Bright Minds Biosciences	N/A	7.04 million	4.04 million	Not Optionable
DSGN Design Therapeutics	40	56.95 million	43.57 million	Optionable
PYXS Pyxis Oncology	60	62.02 million	55.44 million	Optionable
RNAC Cartesian Therapeutics	64	26.00 million	10.32 million	Optionable

PYXS, DSGN, RNAC, and DRUG Headlines

Recent News About These Companies

Mizuho Securities Reaffirms Their Buy Rating on Cartesian Therapeutics (RNAC)

August 15, 2025 | theglobeandmail.com

BTIG Reaffirms Their Buy Rating on Cartesian Therapeutics (RNAC)

August 14, 2025 | theglobeandmail.com

Oppenheimer Sticks to Their Hold Rating for Cartesian Therapeutics (RNAC)

August 14, 2025 | theglobeandmail.com

Cartesian (RNAC) Q2 Revenue Drops 99%

August 9, 2025 | theglobeandmail.com

Cartesian Therapeutics Reports Positive Q2 2025 Earnings

August 8, 2025 | tipranks.com

Cartesian Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 7, 2025 | taiwannews.com.twT

Cartesian Therapeutics (RNAC) to Release Quarterly Earnings on Thursday

August 7, 2025 | marketbeat.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives Consensus Recommendation of "Moderate Buy" from Analysts

August 4, 2025 | marketbeat.com

Cartesian Therapeutics, Inc. (RNAC) Moves 9.9% Higher: Will This Strength Last?

July 24, 2025 | zacks.com

Wedbush Initiates Coverage of Cartesian Therapeutics (RNAC) with Outperform Recommendation

July 9, 2025 | msn.com

We're Not Very Worried About Cartesian Therapeutics' (NASDAQ:RNAC) Cash Burn Rate

June 21, 2025 | finance.yahoo.com

Cartesian Therapeutics holds annual stockholders meeting

June 17, 2025 | investing.com

Cartesian Therapeutics Announces New Employment Inducement Grants

June 3, 2025 | globenewswire.com

BTIG Sticks to Their Buy Rating for Cartesian Therapeutics (RNAC)

June 2, 2025 | theglobeandmail.com

Cartesian Therapeutics Announces First Participant Enrolled in the Phase 3 AURORA Trial of Descartes-08 in Patients with Myasthenia Gravis

May 30, 2025 | globenewswire.com

Cartesian Therapeutics to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ

May 13, 2025 | manilatimes.netM

Analysts Are Bullish on Top Healthcare Stocks: Harrow Health (HROW), Cartesian Therapeutics (RNAC)

May 11, 2025 | theglobeandmail.com

Cartesian Therapeutics (RNAC) Gets a Buy from Mizuho Securities

May 11, 2025 | theglobeandmail.com

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Just Released Its First-Quarter Results And Analysts Are Updating Their Estimates

May 11, 2025 | finance.yahoo.com

Cartesian Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025 | globenewswire.com

Why Cartesian Therapeutics, Inc. (RNAC) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential

May 5, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PYXS, DSGN, RNAC, and DRUG Company Descriptions

Bright Minds Biosciences NASDAQ:DRUG

$43.96 +1.83 (+4.34%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$43.94 -0.02 (-0.06%)

As of 08/22/2025 06:06 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

Design Therapeutics NASDAQ:DSGN

$5.26 +0.11 (+2.14%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$5.08 -0.18 (-3.33%)

As of 08/22/2025 07:50 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Pyxis Oncology NASDAQ:PYXS

$1.34 +0.02 (+1.52%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$1.36 +0.02 (+1.49%)

As of 08/22/2025 07:38 PM Eastern

Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors. The company is also developing PYX-107, a CD40 agonist with demonstrated anti-cancer activity in patients who previously progressed on PD-(L)1 inhibitors, which is in Phase 2 clinical trial for the treatment of solid tumors, such as soft tissue sarcomas, esophageal and gastroesophageal junction, cancers, and melanoma in combination with chemotherapy, radiation therapy, and immunotherapy. It has in-license agreement with Pfizer Inc. to develop and commercialize ADC product candidates directed to certain licensed targets, including PYX-201 and PYX-203, and products containing the ADC product candidates; and Biosion USA, Inc. for development, manufacture, and commercialization of PYX-106, an IO product candidate. Pyxis Oncology, Inc. was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Cartesian Therapeutics NASDAQ:RNAC

$11.23 +0.27 (+2.46%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$11.19 -0.04 (-0.36%)

As of 08/22/2025 05:18 PM Eastern

Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time